Review of management issues in relapsed osteosarcoma

Expert Review of Anticancer Therapy

Volumn 14, Issue 2, 2014, Pages 151-161

  Vijayamurugan, Nataraj ^a   Bakhshi, Sameer ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

osteosarcoma; relapse; treatment

Indexed keywords

ADOLESCENT; BONE NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; PROGNOSIS; SURVIVAL RATE;

EID: 84893300625     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.863453     Document Type: Review

References (102)

1. Arndt CAS, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N. Engl. J. Med. 341(5), 342-352 (1999).
2. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N. Engl. J. Med. 314(25), 1600-1606 (1986).
3. Meyers PA, Gorlick R. Osteosarcoma. Pediatr. Clin. North. Am. 44(4), 973-989 (1997).
4. Ferguson WS, Harris MB, Goorin AM, et al. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial. J. Pediatr. Hematol. Oncol. 23(6), 340-348 (2001).
5. Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J. Clin. Oncol. 20(2), 426-433 (2002).
6. Martini N, Huvos AG, Mike V, Marcove RC, Beattie EJ Jr. Multiple pulmonary resections in the treatment of osteogenic sarcoma. Ann. Thorac. Surg. 12(3), 271-280 (1971).
7. Putnam JB Jr, Roth JA, Wesley MN, Johnston MR, Rosenberg SA. Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: analysis of prognostic factors. Ann. Thorac. Surg. 36(5), 516-23 (1983).
8. Arndt CAS, Koshkina NV, Inwards CY, et al. inhaled gm-csf for first pulmonary recurrence of osteosarcoma; effects on disease free survival animmunomodulation: a report from the childrens oncology group. Clin. Cancer Res. 16(15), 4024-4030 (2010).
9. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann. Oncol. 23(2), 508-516 (2012).
10. Nakase M, Inui M, Okumura K, Kamei T, Nakamura S, Tagawa T. p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol. Cancer Ther. 4(4), 625-631 (2005).
11. Saeter G, Høie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 75(5), 1084-1093 (1995).
12. Giuliano AE, Feig S, Eilber FR. Changing metastatic patterns of osteosarcoma. Cancer 54(10), 2160-2164 (1984).
13. Jaffe N, Smith E, Abelson HT, Frei E. Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy. J. Clin. Oncol. 1(4), 251-254 (1983).
14. Goorin AM, Shuster JJ, Baker A, Horowitz ME, Meyer WH, Link MP. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J. Clin. Oncol. 9(4), 600-605 (1991).
15. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study groups protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann. Oncol. 9(8), 893-899 (1998).
16. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat. Rev. 32(6), 423-436 (2006).
17. Marina NM, Pratt CB, Rao BN, Shema SJ, Meyer WH. Improved prognosis of children with osteosarcoma metastatic to the lung[s] at the time of diagnosis. Cancer 70(11), 2722-2727 (1992).
18. Ward WG, Mikaelian K, Dorey F, et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J. Clin. Oncol. 12(9), 1849-1858 (1994).
19. Goorin AM, Delorey MJ, Lack EE, et al. Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of patients. J. Clin. Oncol. 2(5), 425-431 (1984).
20. Huth JF, Eilber FR. Patterns of recurrence after resection of osteosarcoma of the extremity. Strategies for treatment of metastases. Arch. Surg. 124(1), 122-126 (1989).
21. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J. Clin. Oncol. 21, 710-715 (2003).
22. Bacci G, Ferrari S, Longhi A, et al. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur. J. Cancer 37(1), 32-38 (2001).
23. Grimer RJ, Taminiau AM, Cannon SR. Surgical outcomes in osteosarcoma. J. Bone Joint Surg. Br. 84(3), 395-400 (2002).
24. Chi SN, Conklin LS, Qin J, et al. The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pediatr. Blood Cancer 42(1), 46-51 (2004).
25. Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group [COSS]. J. Clin. Oncol. 23(3), 559-568 (2005).
26. Dahlin DC, Coventry MB. Osteogenic sarcoma. A study of six hundred cases. J. Bone Joint Surg. Am. 49(1), 101-110 (1967).
27. Jeffree GM, Price CH, Sissons HA. The metastatic patterns of osteosarcoma. Br. J. Cancer 32(1), 87-107 (1975).
28. Sweetnam R. The surgical management of primary osteosarcoma. Clin. Orthop. Relat. Res. (111), 57-64 (1975).
29. Bacci G, Ruggieri P, Picci P, et al. Changing pattern of relapse in osteosarcoma of the extremities treated with adjuvant andneoadjuvant chemotherapy. J. Chemother. 7, 230-239 (1995).
30. Goldstein H, McNeil BJ, Zufall E, Jaffe N, Treves S. Changing indications for bone scintigraphy in patients with osteosarcoma. Radiology 135(1), 177-180 (1980).
31. Lindner NJ, Ramm O, Hillmann A, et al. Limb salvage and outcome of osteosarcoma. The University of Muenster experience. Clin. Orthop. Relat. Res. (358), 83-89 (1999).
32. Sluga M, Windhager R, Lang S, Heinzl H, Bielack S, Kotz R. Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin. Orthop. Relat. Res. (358), 120-127(1999).
33. Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J. Clin. Oncol. 27(4), 557-565 (2009).
34. Hawkins DS, Arndt CAS. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 98(11), 2447-2456 (2003).
35. Duffaud F, Digue L, Mercier C, et al. Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy. Eur. J. Cancer 39(14), 2050-2057 (2003).
36. Rosenburg SA, Flye MW, Conkle D, Seipp CA, Levine AS, Simon RM. Treatment of osteogenic sarcoma. II. Aggressive resection of pulmonary metastases. Cancer Treat. Rep. 63(5), 753-756 (1979).
37. Carter SR, Grimer RJ, Sneath RS, Matthews HR. Results of thoracotomy in osteogenic sarcoma with pulmonary metastases. Thorax 46(10), 727-731 (1991).
38. Pastorino U, Gasparini M, Tavecchio L, et al. The contribution of salvage surgery to the management of childhood osteosarcoma. J. Clin. Oncol. 9(8), 1357-1362 (1991).
39. Ellis PM, Tattersall MH, McCaughan B, Stalley P. Osteosarcoma and pulmonary metastases: 15-year experience from a single institution. Aust. NZ J. Surg. 67(9), 625-629 (1997).
40. Briccoli A, Rocca M, Salone M, Guzzardella GA, Balladelli A, Bacci G. High grade osteosarcoma of the extremities metastatic to the lung: long-term results in patients treated combining surgery and chemotherapy 1985-2005. Surg. Oncol. 19(4), 193-199 (2010).
41. Heij HA, Vos A, de Kraker J, Voute PA. Prognostic factors in surgery for pulmonary metastases in children. Surgery 115(6), 687-693 (1994).
42. Meyer WH, Schell MJ, Kumar AP, et al. Thoracotomy for pulmonary metastatic osteosarcoma. An analysis of prognostic indicators of survival. Cancer 59(2), 374-379 (1987).
43. Han MT, Telander RL, Pairolero PC, et al. Aggressive thoracotomy for pulmonary metastatic osteogenic sarcoma in children and young adolescents. J. Pediatr. Surg. 16(6), 928-933 (1981).
44. Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, et al. Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. J. Clin. Oncol. 20(16), 3470-3477 (2002).
45. Ferrari S, Bacci G, Picci P, et al. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann. Oncol. 8(8), 765-771 (1997).
46. Zaharia M, Caceres E, Valdivia S, Moran M, Tejada F. Postoperative whole lung irradiation with or without adriamycin in osteogenic sarcoma. Int. J. Radiat. Oncol. Biol. Phys. 12(6), 907-910 (1986).
47. Rosen G, Suwansirikul S, Kwon C, et al. High-dose methotrexate with citrovorum rescue factor and adriamycin in childhood osteogenic sarcoma. Cancer 33, 1151-1163 (1974).
48. Beattie E, Martini N, Rosen G. The management of pulmonary metastases in children with osteogenic sarcoma with surgical resection combined with chemotherapy. Cancer 35, 618-621 (1975).
49. Chou AJ, Merola PR, Wexler LH, et al. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 104(10), 2214-2149 (2005).
50. Bacci G, Briccoli A, longhi A, et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in patients initially treated with neoadjuvant chemotherapy. Acta Oncol. 44, 748-755 (2005).
51. Crompton BD, Goldsby RE, Weinberg VK, Feren R, ODonnell RJ, Ablin AR. Survival after recurrence of osteosarcoma: a 20-year experience at a single institution. Pediatr. Blood Cancer 47(3), 255-259 (2006).
52. Berrak SG, Pearson M, Berberoglu S, Ilhan IE, Jaffe N. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr Blood Cancer 44(3), 215-219 (2005).
53. Berger M, Massimo B, Grignani G, et al. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer 115(13), 2980-2987 (2009).
54. Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 113(2), 419-425 (2008).
55. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol. 20(3), 776-790 (2002).
56. Harting MT, Blakely ML, Jaffe N, et al. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J. Pediatr. Surg. 41(1), 194-199 (2006).
57. Thompson RC Jr, Cheng EY, Clohisy DR, Perentesis J, Manivel C, Le CT. Results of treatment for metastatic osteosarcoma with neoadjuvant chemotherapy and surgery. Clin. Orthop. Relat. Res. (397), 240-247 (2002).
58. Nathan SS, Gorlick R, Bukata S, et al. Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastases. Cancer 107(7), 1607-1616 (2006).
59. Picci P, Sangiorgi L, Rougraff BT, Neff JR, Casadei R, Campanacci M. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J. Clin. Oncol. 12(12), 2699-2705 (1994).
60. Picci P, Sangiorgi L, Bahamonde L, et al. Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities. Ann. Oncol. 8(9), 899-903 (1997).
61. Weeden S, Grimer RJ, Cannon SR, Taminiau AH, Uscinska BM. The effect of local recurrence on survival in resected osteosarcoma. Eur. J. Cancer 37(1), 39-46 (2001).
62. Kawai A, Huvos AG, Meyers PA, Healey JH. Osteosarcoma of the pelvis. Oncologic results of 40 patients. Clin. Orthop. 196-207 (1998).
63. Winkler K, Bieling P, Bielack S, et al. Local control and survivalfrom the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry. Clin. Orthop. Relat. Res. 270, 79-86 (1991).
64. Brosjo O. Surgical procedure and local recurrence in 223 patients treated 1982- 1997 according to two osteosarcoma chemotherapy protocols. The Scandinavian Sarcoma Group experience. Acta. Orthop. Scand. Suppl. 285, 58-61 (1999).
65. Bacci G, Forni C, Longhi A, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J. Surg. Oncol. 96(2), 118-123 (2007).
66. Rodriguez-Galindo C, Shah N, McCarville MB, et al. Outcome after local recurrence of osteosarcoma:the St. Jude Childrens Research Hospital experience [1970-2000]. Cancer 100(9), 1928-1935 (2004).
67. Bacci G, Longhi A, Cesari M, Versari M, Bertoni F. Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients. Cancer 106(12), 2701-2706 (2006).
68. Andreou D, Bielack SS, Carrle D, et al. The influence of tumor-and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. Ann. Oncol. 22(5), 1228-1235 (2011).
69. Lee HJ, Kim IO, Kim WS, Cheon JE, Kim KW, Yeon KM. Metachronous multifocal osteosarcoma: a case report and literature review. Clin. Imaging 26(1), 63-68 (2002).
70. Simodynes EE, Jardon OM, Connolly JF. Multiple metachronous osteosarcoma with eleven-year survival. A case report. J. Bone Joint Surg. Am. 63(2), 317-322 (1981).
71. Howat AJ, Dickens DR, Boldt DW, Waters KD, Campbell PE. Bilateral metachronous periosteal osteosarcoma. Cancer 58(5), 1139-1143 (1986).
72. Aung L, Gorlick R, Healey JH, et al. Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma. J. Clin. Oncol. 21(2), 342-348 (2003).
73. Jaffe N, Pearson P, Yasko AW, Lin P, Herzog C, Raymond K. Single and multiple metachronous osteosarcoma tumors after therapy. Cancer 98(11), 2457-2466 (2003).
74. Bacci G, Longhi A, Bertoni F, et al. Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients. Acta Orthop. 77(6), 938-943 (2006).
75. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin. Orthop. Relat. Res. (397), 40-52 (2002).
76. Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J. Clin. Oncol. 20(1), 189-196 (2002).
77. Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J. Clin. Oncol. 21(2), 334-341 (2003).
78. Anderson PM, Wiseman GA, Erlandson L, et al. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin. Cancer Res. 11(19 Pt 1), 6895-6900 (2005).
79. Briccoli A, Rocca M, Salone M, et al. Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer 104(8), 1721-1725 (2005).
80. Sauerbrey A, Bielack S, Kempf-Bielack B, Zoubek A, Paulussen M, Zintl F. High-dose chemotherapy [HDC] and autologous hematopoietic stem cell transplantation [ASCT] as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant. 27, 933-937 (2001).
81. Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J. Clin. Oncol. 20(8), 2150-2156 (2002).
82. Franzius C, Bielack S, Flege S, et al. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin 40(6), 215-220 (2001).
83. Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide [CGP 19835A] in the treatment of relapsed osteosarcoma. Am. J. Clin. Oncol. 18(2), 93-99 (1995).
84. Arndt CAS, Koshkina NV, Inwards CY, et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Childrens Oncology Group. Clin. Cancer Res. 16(15), 4024-4030 (2010).
85. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77(1), 71-78 (1996).
86. Chou AJ, Gupta R, Bell MD, Riewe KO, Meyers PA, Gorlick R. Inhaled lipid cisplatin [ILC] in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. Pediatr. Blood Cancer 60(4), 580-586 (2013).
87. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol. Med. 10(5), 201-204 (2004).
88. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med. 10(2), 182-186 (2004).
89. Lafleur EA, Koshkina NV, Stewart J, et al. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin. Cancer Res. 10(23), 8114-8119 (2004).
90. Gordon N, Arndt CAS, Hawkins DS, et al. Fas expression in lung metastasis from osteosarcoma patients. J. Pediatr. Hematol. Oncol. 27(11), 611-615 (2005).
91. Takenaka K, Yamagishi S-I, Jinnouchi Y, Nakamura K, Matsui T, Imaizumi T. Pigment epithelium-derived factor [PEDF]-induced apoptosis and inhibition of vascular endothelial growth factor [VEGF] expression in MG63 human osteosarcoma cells. Life Sci. 77(25), 3231-3241 (2005).
92. Broadhead ML, Dass CR, Choong PFM. Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model. Br. J. Cancer 105(10), 1503-1511 (2011).
93. Fisher JL, Mackie PS, Howard ML, Zhou H, Choong PF. The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. Clin. Cancer Res. 7(6), 1654-1660 (2001).
94. Dass CR, Nadesapillai APW, Robin D, et al. Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin. Exp. Metastasis. 22(8), 643-652 (2005).
95. Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery [neoadjuvant chemotherapy] for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate [high versus moderate doses] and intraarterial cisplatin. Cancer 65(11), 2539-2553 (1990).
96. Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int. J. Cancer 116(3), 458-463 (2005).
97. Federman N, Chan J, Nagy JO, et al. Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma 2012, 126906 (2012).
98. Browning MB, Russell B, Rivera J, Höök M, Cosgriff-Hernandez EM. Bioactive hydrogels with enhanced initial and sustained cell interactions. Biomacromolecules 14(7), 2225-2233 (2013).
99. Ta HT, Dass CR, Larson I, Choong PF, Dunstan DE. A chitosan hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor combined with chemotherapy. Biomaterials 30(27), 4815-4823 (2009).
100. Kaya M, Wada T, Kawaguchi S, et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br. J. Cancer 86(6), 864-869 (2002).
101. Bajpai J, Sharma M, Sreenivas V, Kumar R, et al. VEGF expression as a prognostic marker in osteosarcoma. Pediatr. Blood Cancer 53(6), 1035-1039 (2009).
102. Mori S, Ueda T, Kuratsu S, Hosono N, Izawa K, Uchida A. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int. J. Cancer. 61(1), 148-152 (1995).